

**2022 Cardiology Pharmacy Specialty Recertification Literature Study:
Module 1B: Updates in Antiplatelets, Cardiomyopathy and Cardiogenic Shock**

Articles and Learning Objectives

Cardiology Pharmacy Literature Study Module 1B: Updates in Antiplatelets, Cardiomyopathy and Cardiogenic Shock

ACPE #: 0204-9999-22-959-H01-P

Contact Hours: 3.5

Activity Type: Application-based

This module focuses on new treatments for cardiomyopathy, as well as updates on antiplatelet use after percutaneous coronary intervention and treatments for cardiogenic shock.

Koo BK, Kang J, Park KW et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. *Lancet*. 2021; 397:2487-96.

Learning Objectives:

- Describe the HOST-EXTended Antiplatelet Monotherapy (HOST-EXAM) trial by Koo and colleagues comparing aspirin with clopidogrel as chronic maintenance monotherapy after percutaneous coronary intervention and drug-eluting stent placement.
- Develop recommendations for the use of chronic maintenance antiplatelet monotherapy as secondary prevention of atherosclerotic cardiovascular events after successful completion of recommended dual antiplatelet therapy (DAPT) in patients with coronary artery disease (CAD), percutaneous coronary intervention (PCI), and drug-eluting stent (DES) placement.

Valgimigli M, Frigoli, Heg D et al. Dual antiplatelet therapy after PCI in patients at high bleeding risk. *N Engl J Med*. 2021; 385:1643-55.

Learning Objectives:

- Describe the MASTER DAPT trial by Valgimigli and colleagues.
- Develop recommendations for the duration of dual antiplatelet therapy (DAPT) in patients with an acute or chronic coronary syndrome who are at high risk for bleeding after successful percutaneous coronary intervention (PCI) with drug-eluting stent (DES) placement.

Escaned J, Cao D, Baber U et al. Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. *Eur Heart J*. 2021; 42:4624-34.

Learning Objectives:

- Describe the prespecified analysis by Escaned and colleagues of a subset of TWILIGHT trial participants at high bleeding risk (HBR).
- Develop recommendations for antiplatelet therapy in patients who are at high risk for bleeding after successful percutaneous coronary intervention (PCI) with drug-eluting stent (DES) placement.

Olivotto I, Oreziak A, Barriales-Villa R et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2020; 396:759-69.

Learning Objectives:

- Describe the EXPLORER-HCM trial by Olivotto and colleagues of mavacamten for treating patients with symptomatic obstructive hypertrophic cardiomyopathy.
- Develop recommendations for the use of mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.

Mathew R, Di Santo P, Jung RG et al. Milrinone as compared with dobutamine in the treatment of cardiogenic shock. *N Engl J Med*. 2021; 385:516-25.

Learning Objectives:

- Describe the Dobutamine Compared with Milrinone (DOREMI) trial.
- Develop recommendations for the use of inotropic therapy in patients with cardiogenic shock.